Phaseline

Companies › Hope Biosciences Research Foundation

Hope Biosciences Research Foundation: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Immunology, Neurology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Autologous HB-adMSCs
Autologous adipose-derived mesenchymal stem cells
–Phase 2Relapsing Remitting Multiple Sclerosis (RRMS)Jan 2027
HB-adMSCs (Hope Biosciences Adipose Derived Mesenchymal Stem Cells)
Allogeneic adipose-derived mesenchymal stem cells
–Phase 2Crohn Disease (CD)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06800404Autologous HB-adMSCsPhase 2Relapsing Remitting Multiple Sclerosis (RRMS)NeurologyJan 2027
NCT07077746HB-adMSCs (Hope Biosciences Adipose Derived Mesenchymal Stem Cells)Phase 2Crohn Disease (CD)ImmunologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Kyverna Therapeutics Autolus Nature Cell Throne Biotechnologies Nippon Shinyaku

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.